ImCheck Presents Preliminary Patient Response Data from the Phase I/IIa EVICTION Trial with ICT01 at ESMO Congress 2021

September 17, 2021

ImCheck Therapeutics today announced that it will present updated clinical data from the ongoing EVICTION Phase I/IIa trial evaluating ICT01, a first-in-class Butyrophilin (BTN) 3A-targetingmonoclonal antibody, in patients with advanced, relapsed/refractory solid and hematological cancers, in an oral presentation at the ESMO Congress 2021. The conference will take place virtually from September 16 – 21, 2021.

“The ESMO Congress is one of the most prominent cancer meetings of the year at which to present clinical data and we are excited to share the continued progress of our ongoing EVICTION trial evaluating ICT01 alone and in combination with pembrolizumab in patients with refractory solid tumors,” said Paul Frohna, MD, PhD, Chief Medical Officer at ImCheck Therapeutics.https://www.imchecktherapeutics.com/all-press-release/news/imcheck-to-present-early-patient-response-data-from-the-eviction-trial-at-the-esmo-congress-2021/https://www.imchecktherapeutics.com/all-press-release/news/imcheck-to-present-early-patient-response-data-from-the-eviction-trial-at-the-esmo-congress-2021/